Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11736626 | 0.87 | MAPT (0.76) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25493925 | 0.87 | HPGD (0.61) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3763530 | 0.87 | LMNA (0.62) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3049167 | 0.87 | MAPT (0.62) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5243267 | 0.87 | SIRT6 (0.68) | HPGDMAPTALDH1A1L3MBTL1LMNA | |
| SCHEMBL4878889 | 0.87 | SIRT6 (0.68) | HPGDMAPTALDH1A1L3MBTL1LMNA | |
| SCHEMBL31423825 | 0.87 | ALDH1A1 (0.59) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL939887 | 0.86 | SIRT6 (0.74) | MAPTALDH1A1L3MBTL1SIRT6MAPK1 | |
| SCHEMBL1414539 | 0.86 | MAPT (0.64) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL940811 | 0.86 | MAPT (0.78) | MAPTALDH1A1CYP2C19CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2590965-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2590965-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9289430-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289429-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289429-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289429-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2590655-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2015-06-24 | — | — | EP | disclosed |
| WO-2012006473-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| US-5580870-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0602851-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1996-10-09 | — | — | EP | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0602851-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1994-06-22 | — | — | EP | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | HPGD 3637/4885MAPT 3414/4885ALDH1A1 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.